PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients ...
CARMEL, Ind., Dec. 02, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies ...
This article is based on a poster originally authored by Chris Bohl, Ken Brouwer, Karissa Cottier, Scott Heyward, Courtney Noah, Brian Ogilvie, and BioIVT. Several reports in the literature have ...
Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 metabolic dysfunction-associated steatohepatitis (MASH) study, while still ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results